Mayo Clinic laboratory and pathology research roundup: June 29

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.

Androgen receptor (AR) is a major survival factor for prostate cancer (PCa). Inflammation is implicated in many cancer types including PCa. Activation of MAP3K7 (also termed TAK1) and downstream IκB kinase β (IKKβ) by pro-inflammatory cytokines such as TNFα stimulates NF-κB survival pathways. Paradoxically, MAP3K7 is often deleted in human PCa. Here we demonstrate that AR protein expression is lower in inflammatory tumor areas compared to non-inflammatory tissues in PCa patients. Via Cancer Research

Read more.

Published to PubMed This Week

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.